The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.
May 14th 2024
A US-based discrete choice experiment survey found that patients with atopic dermatitis (AD) prioritize treatments that effectively control itching.
House Dust Mite Sublingual Immunotherapy Shows Promise in Atopic Dermatitis
March 23rd 2022Sublingual immunotherapy with Dermatophagoides pteronyssinus extract was associated with significant improvements in disease severity among patients with atopic dermatitis sensitized to the house dust mite.
Read More
Dr Robert Sidbury Addresses Quality-of-Life Burden in Atopic Dermatitis
March 17th 2022Along with common symptoms of itch and pain, patients with atopic dermatitis experience significant work productivity and attention issues that affect overall quality of life, said Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital.
Watch
Upadacitinib Shows Sustained Efficacy, Safety in Moderate to Severe Atopic Dermatitis
March 15th 2022Longer-term findings of the Measure Up 1 and 2 studies showed the JAK inhibitor upadacitinib to be safe and effective after 52 weeks in the treatment of adults and adolescents with moderate to severe atopic dermatitis.
Read More
Dr Robert Sidbury on Psychosocial, Behavioral Issues Linked With Atopic Dermatitis
March 13th 2022Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, discussed the psychosocial and behavioral issues faced by patients with atopic dermatitis, particularly those with severe disease.
Watch
Skin Barrier Function in Moderate to Severe AD Significantly Improved With Dupilumab
March 9th 2022Dupilumab was shown to significantly improve factors of skin barrier function, including transepidermal water loss, lipid composition, and filaggrin, among patients with moderate to severe atopic dermatitis.
Read More
Multidisciplinary Approach Identifies Allergic, Immunology Burden in Severe AD
March 4th 2022Patients with severe atopic dermatitis showed significant associations with concomitant contact dermatitis and immune dysfunction after undergoing a multidisciplinary evaluation between allergy, immunology, and dermatology specialists.
Read More
Dr Robert Sidbury Discusses Utilization, Efficacy of Biologics for Atopic Dermatitis
February 24th 2022Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the efficacy of biologics in the treatment of atopic dermatitis and other recently approved therapeutics.
Watch
Dupilumab Significantly Reduces Hospitalization Rates in Patients With Atopic Dermatitis
January 27th 2022Patients with atopic dermatitis (AD) treated with dupilumab showed reduced hospitalization rates and shorter duration of AD-related hospitalizations vs those treated with control therapies.
Read More
Real-World Study Finds Dupilumab Safe, Effective for Moderate-to-Severe Atopic Dermatitis
January 6th 2022Korean patients with moderate-to-severe atopic dermatitis achieved and maintained markedly improved skin clearance with dupilumab treatment in a real-world setting, including in the face and hands.
Read More
Dr David R. Stukus Spotlights Unmet Needs in Atopic Dermatitis Management
December 28th 2021David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the lack of interventions to manage the underlying causes of exacerbation in atopic dermatitis.
Watch
Evaluating Differences in Therapeutic, Diagnostic Approaches to Atopic Dermatitis
December 24th 2021A study found significant differences in the therapeutic and diagnostic approaches to atopic dermatitis used by allergists, dermatologists, and pediatricians, and those recommended by guidelines.
Read More
Dr David R. Stukus Discusses Access, Affordability Concerns of Emerging Atopic Dermatitis Therapies
December 22nd 2021David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the difficulties of gaining coverage for newer biologic therapies in the treatment of atopic dermatitis.
Watch
Dupilumab Shows High Effectiveness in AD for Ages 6 Months and Up
December 18th 2021Research presented at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference said dupilumab (Dupixent) is an effective and safe therapeutic option in adults, adolescents aged 6 to 11 years, and young children aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
Read More
Dr David R. Stukus on Immune-Related Response to Therapy in Atopic Dermatitis
December 17th 2021David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, discusses efforts to align novel treatments for atopic dermatitis with patients based on the underlying mechanisms of disease.
Watch